Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
Amneal Pharmaceuticals said the FDA approved its ready-to-use romidepsin injection solution (27.5 mg/5.5 mL) in single-dose vials. The drug received Competitive Generic Therapy (CGT) designation, granting Amneal 180 days of market exclusivity. Amneal said the product references a Teva romidepsin liquid previously withdrawn. IQVIA data cited about $78 million in U.S. sales for the prior lyophilized form.
Approval plus CGT exclusivity can drive near-term sentiment and support revenue ramp expectations for the reintroduced product.
FDA approved Amneal’s romidepsin injection solution, enabling CGT designation and 180 days of market exclusivity for its oncology injectables.
Likely positive bias for AMRX with potential follow-through if investors price in exclusivity-driven share gains.
Background
Romidepsin is an HDAC inhibitor for cutaneous T-cell lymphoma; Amneal’s approval is for a ready-to-use single-dose vial formulation eligible for CGT designation.
Why it matters
FDA approval reintroduces a previously withdrawn romidepsin injection solution and grants 180 days of market exclusivity, which can improve Amneal’s near-term commercialization outlook.
Market relevance
A discrete regulatory milestone with exclusivity is typically tradable for oncology/generic injectables names, especially when tied to a specific product and exclusivity window.
Market effects
Reinforces demand for oncology injectables and the value of CGT-designated generic/complex injectables in oncology.
Limited; company is New Jersey-based and the catalyst is FDA approval (national).
Low; the approval is US-specific, though it may inform broader commercialization strategy.
Alternative perspectives
CGT exclusivity may not translate into large incremental revenue if competitive supply, reimbursement, or hospital formulary adoption limits uptake.
The article references prior Teva product withdrawal and historical sales, but does not address current competitive landscape, manufacturing capacity, or expected launch timing/uptake.
Key entities
- companyAmneal Pharmaceuticals
Receives FDA approval for romidepsin injection solution and CGT designation.
- regulatorFDA
Approved the romidepsin injection solution and enabled CGT eligibility.
- companyTeva
Previously marketed the referenced romidepsin solution that was withdrawn.
